PSPC1 Inhibition Synergizes with Poly(ADP-ribose) Polymerase Inhibitors in a Preclinical Model of BRCA-Mutated Breast/Ovarian Cancer Authors: Mithun Ghosh, Min Sil Kang, Nar Bahadur Katuwal, Sa Deok Hong, Yeong Gyu Jeong, Seong Min Park, Seul-Gi Kim, Yong Wha Moon, Masa-Aki Shibata, Sasagu Kurozumi Published: 2023 ABSTRACT AbstractPoly (ADP-ribose) polymerase (PARP) inhibitors are effective against BRCA1/2-mutated cancers through synthetic lethality. Unfortunately, most cases ultimately develop acquired resistance. Therefore, enhancing PARP inhibitor sensitivity and preventing resistance in those cells are an unmet clinical need. Here, we investigated the ability of paraspeckle component 1 (PSPC1), as an additional synthetic lethal partner with BRCA1/2, to enhance olaparib sensitivity in preclinical models of BRCA1/2-mutated breast and ovarian cancers. In vitro, the combined olaparib and PSPC1 small interfering RNA (siRNA) exhibited synergistic anti-proliferative activity in BRCA1/2-mutated breast and ovarian cancer cells. The combination therapy also demonstrated synergistic tumor inhibition in a xenograft mouse model. Mechanistically, olaparib monotherapy increased the expressions of p-ATM and DNA-PKcs, suggesting the activation of a DNA repair pathway, whereas combining PSPC1 siRNA with olaparib decreased the expressions of p-ATM and DNA-PKcs again. As such, the combination increased the formation of γH2AX foci, indicating stronger DNA double-strand breaks. Subsequently, these DNA-damaged cells escaped G2/M checkpoint activation, as indicated by the suppression of p-cdc25C (Ser216) and p-cdc2 (Tyr15) after combination treatment. Finally, these cells entered mitosis, which induced increased apoptosis. Thus, this proves that PSPC1 inhibition enhances olaparib sensitivity by targeting DNA damage response in our preclinical model. The combination of olaparib and PSPC1 inhibition merits further clinical investigation to enhance PARP inhibitor efficacy.Keywords: PARP inhibitor, PSPC1, DNA double-strand break, sensitivity 1. Introduction BRCA1 and BRCA2 (BRCA1/2) are important genes involved in homologous recombination (HR) repair, particularly in the repair of DNA double-strand breaks (DSBs) [1]. Hence, BRCA1/2, which act as tumor suppressors, suppress genetic instability [2]. From the therapeutic perspective, cancer cells with BRCA1/2 mutations are very sensitive to poly (ADP-ribose) polymerase (PARP) inhibitors because PARP inhibitors cause an increase in DNA single-strand breaks, which are then converted to irreparable toxic DNA DSBs in those cells during replication [3]. The prevalence of BRCA1/2 mutations is highest in ovarian cancer (21%) [4] and around 5% in several other cancers, including breast [5], prostate [6], pancreatic [7], non-small cell lung [8], bladder [9], and bile duct [10] cancers. In particular, subsets of certain cancers, such as triple-negative breast cancer (10–15%) [5] and castration-resistant prostate cancer (13.6%) [6], have a higher prevalence of BRCA1/2 mutations than does the whole population of that cancer. In BRCA1/2-mutated or HR-deficient (HRD) ovarian cancer, olaparib or niraparib maintenance after first-line paclitaxel/carboplatin significantly prolonged progression-free survival (PFS) in the SOLO1 (13.8 vs. 56 months in the placebo and olaparib groups, respectively) [11] or PRIMA trial (10.4 vs. 21.9 months in the placebo and niraparib groups, respectively) [12]. Improvements in PFS translated to overall survival (OS) benefits in the SOLO1 trial [13]; however, OS data for the PRIMA trial has not been reported yet. In addition, PARP inhibitors, such as talazoparib [14], rucaparib [15], niraparib [16], and olaparib [17] have been approved in for the treatment of the aforementioned cancers with BRCA1/2 mutation by the United States Food and Drug Administration. Though PARP inhibitors are effective therapy for BRCA1/2-mutated cancers, not all patients respond, and most patients ultimately progress on PARP inhibitor therapy. Therefore, enhancing PARP inhibitor sensitivity or preventing BRCA-mutated cells from developing resistance is an unmet need. Considering this fact, the validation of an additional synthetic lethal partner with BRCA1/2 genes or the finding of drug synergism with PARP inhibitors could be a promising therapeutic approach. Initial combinations evaluated DNA-damaging chemotherapy in combination with PARP inhibitors, however, overlapping toxicity such as myelosuppression, limited further development of this combination [18]. To enhance PARP inhibitor activity, then next approaches included targeting DNA damage response (DDR)-associated genes such as ataxia telangiectasia and Rad3-related serine/threonine kinase (ATR) [19], checkpoint kinase 1 (Chk1) [20], and wee1 G2 checkpoint kinase (WEE1) [21]. A synergistic mechanism of this combination is that DNA-damaged cells damaged by PARP inhibitors undergo mitosis without repairing DNA damage resulting in increased apoptosis. In addition, several strategies other than targeting the DDR pathway, including antiangiogenic agents [22] and immune checkpoint inhibitors [23], have been reported. Of all combination partners to enhance PARP inhibitor activity, bevacizumab, a vascular endothelial growth factor inhibitor, only proved clinical efficacy. That is, the phase III PAOLA-1 clinical trial demonstrated the good efficacy of combined olaparib and bevacizumab as a maintenance therapy after first-line chemotherapy in HRD or BRCA-mutated ovarian cancer [24] and finally led to the regulatory approval of this combination. Despite this, we still need to enhance PARP inhibitor activity in various ways in a PARP inhibitor-sensitive setting. Therefore, we tried to search for an additional synthetic lethal partner with BRCA1/2 genes. Paraspeckle component 1 (PSPC1) was identified as structural protein found in paraspeckles. Paraspeckles are nuclear bodies located in the interchromatin space of the cell nucleus adjacent to speckles and these nuclear bodies are primarily composed of three proteins, such as PSPC1, SFPQ (splicing factor proline and glutamine-rich, known as PSF), and NONO (non-POU-domain-containing octamer-binding protein, known as p54nrb) [25]. Regarding the function of PSPC1, there were only limited studies to date, therefore the functions of PSPC1 have not been completely understood. However, based on other studies, PSPC1 has been shown to exhibit RNA-binding activity, involved in mRNA splicing [26], regulating androgen receptor-mediated transcription activity [27]. Moreover, the functions of PSPC1 include viral gene regulation, adipocyte differentiation, and gene regulation [28]. In addition, recruitment of PSPC1 could be promoted to the DNA damage sites by PSF following p54nrb knockdown [29]. Interestingly, PSPC1 was also reported to play a role in cisplatin-induced and methyl methanesulfonate-induced DDR [30,31]. Such reports led us to hypothesize that PSPC1 could be a participant in DDR. Recent studies reported that PSPC1 was associated with various cancers, such as liver cancer, nasopharyngeal cancer, lung cancer and breast cancer, which is a poor prognostic factor for patient survival [32]. Therefore, it motivated us to test the synthetic lethality of PSPC1 inhibition in BRCA1/2-mutated cancer. Herein, we investigated the synergism of PSPC1 inhibition in combination with olaparib in a preclinical model with PSPC1-expressing, BRCA1/2-mutated breast and ovarian cancer, demonstrating the synergistic anticancer activity of the combination. 2. Results 2.1. PSPC1 Inhibition Synergizes with Olaparib in BRCA1/2-Mutated PSPC1-Expressing Cells To evaluate our hypothesis that targeting PSPC1 may enhance the anticancer activity of PARP inhibitors in BRCA-mutated breast or ovarian cancer, we initially analyzed the relationship between PSPC1 expression and olaparib sensitivity in 19 BRCA1/2-mutated ovarian cancer cell lines out of Genomics of Drug Sensitivity in Cancer (GDSC) data. Accordingly, we found a significant inverse relationship (p = 0.011) between olaparib activity and PSPC1 expression (Figure 1A), that is, cells with higher olaparib activity (IC50 < 3.2 µM) showed lower PSPC1 expression than did those with lower olaparib activity (IC50 > 3.2 µM). PSPC1 inhibition synergizes with olaparib in BRCA1/2-mutated PSPC1-expressing cells. (A) Correlation between PSPC1 expression and olaparib sensitivity, which was defined as IC50 ≤ 3.2 µM, in BRCA1/2-mutated ovarian cancer cell lines using GDSC data. p-values were analyzed by Student’s t-test. (B,C) MTT assay showed that combined PSPC1 siRNA and olaparib enhanced the antiproliferative effects in (B) BT−474 and (C) SNU−251 cells. Cells were treated with 5 nM of PSPC1 siRNA and indicated concentrations of olaparib and incubated for 72 h. (D,E) Apoptosis assay carried out by flow cytometry after staining with annexin V-APC/PI, representative scatter plots of PI (y-axis) and annexin V (x-axis). The number of total apoptotic cells were increased after the treatment with combined PSPC1 siRNA (5 nM) and olaparib (IC50 concentration in BT−474 and half IC50 concentration in SNU−251) for 72 h in (D) BT−474 and (E) SNU−251 cells. The data shown here were representative of three independent experiments. The bar graphs depicted the average of total apoptotic cells of three independent experiments. p-values were calculated by one-way ANOVA analysis, indicating ** p < 0.01, *** p < 0.001, **** p < 0.0001. Data are presented as mean ± standard deviation from three independent experiments. (F,G) The expressions of apoptosis markers, caspase−3 and cleaved caspase−3 were analyzed with Western blot in (F) BT−474 and (G) SNU−251 cells. Cells were treated for 72 h with PSPC1 siRNA (5 nM), olaparib (IC50 concentration in BT−474 and half IC50 concentration in SNU−251) and their combination. GAPDH was used as a loading control. Next, we carried out a cell proliferation assay with PSPC1 siRNA (5 nM) and various concentrations of olaparib in BRCA-mutated breast (BT−474, MDA-MB−436) and ovarian cancer (SNU-251, PEO1) cells. The characteristics of these cell lines are summarized in Table S1. Combination treatment synergistically (CI < 1, Figure S1) inhibited the cell proliferation of BRCA1/2-mutated BT−474 and SNU−251 cells as compared to the monotherapy (Figure 1B,C). Moreover, the combination treatment exhibited synergistic effects in MDA-MB−436 and PEO1 cells as well (Figure S2A,B). Notably, synergism was observed even at the minimum concentration among the concentrations tested in this study, which might help reduce the toxicity of the therapy among patients. In addition, an apoptosis assay using annexin V and propidium iodide (PI) also confirmed that the combination of PSPC1 siRNA and olaparib promoted significantly more total apoptotic cells than did PSPC1 siRNA or olaparib alone in both BT−474 and SNU−251 cells (Figure 1D,E). Furthermore, Western blotting showed that the expression of cleaved caspase-3 was increased after combination treatment in both cell lines, indicating the activation of apoptosis (Figure 1F,G). Based on these results, we can hypothesize that the enhanced apoptosis induced by combined PSPC1 inhibition and olaparib could be attributed to their synergistic effects. 2.2. PSPC1 Inhibition Enhances DNA DSBs by Inhibiting Olaparib-Induced DDR Next, to investigate the mechanisms behind the aforementioned apoptosis, we assessed the expression of DDR-associated genes because olaparib affects DNA damage based on its mechanism of action. We initially analyzed the expression of ɣH2AX as a DNA DSBs marker and observed that olaparib monotherapy increased the expression of ɣH2AX. However, when PSPC1 siRNA was combined with olaparib, a robust expression of ɣH2AX was observed in both BT−474 and SNU−251 cells (Figure 2A,B), suggesting the combination therapy was able to induce more profound DNA DSBs. In addition, the immunocytochemistry staining showed that combination treatment promoted greater formation of ɣH2AX foci than did monotherapy in both cell lines (Figure 2C,D). PSPC1 inhibition enhances DNA DSBs by inhibiting olaparib-induced DDR. (A,B) Western blot was performed to analyze the expressions of DDR-related proteins in (A) BT−474 and (B) SNU−251 cells. Cells were treated with 5 nM of PSPC1 siRNA, olaparib (IC50 concentration in BT−474 and half IC50 concentration in SNU−251) and their combination for 72 h. GAPDH was used as a loading control. (C,D) Immunofluorescence was carried out to capture the ɣH2AX foci formation in (C) BT−474 and (D) SNU−251 cells as a DNA DSBs marker. The cells were incubated for 48 h after treatment with PSPC1 siRNA (5 nM), olaparib (IC50 concentration in BT−474 and half IC50 concentration in SNU−251), and their combination. The images were taken at 100x magnification. The images shown here were representative of three independent experiments. The bar graphs depicted the average foci number per cell of three independent experiments. The foci were counted in 10 cells for each group. P-values were calculated by one-way ANOVA analysis, indicating **** p < 0.0001. Data are presented as mean ± standard deviation from 3 independent experiments. BRCA1/2-mutated cells are known to be HRD and based on the reports, those HRD cells rely on the non-homologous end joining (NHEJ) pathway for DSB repair [33]. Hence, we evaluated the expression of NHEJ pathway-related genes and noticed that olaparib treatment induced the expression of the DNA-dependent protein kinase catalytic subunit (DNA-PKcs), indicating that the NHEJ-mediated DSB repair pathway was activated [34]. However, the combination therapy inhibited the expression of DNA-PKcs again, suggesting that the olaparib-induced DDR via NHEJ was decreased when PSPC1 was inhibited, leading to more profound DNA damage (Figure 2A,B). Based on previous reports that ataxia-telangiectasia mutated (ATM) plays some crucial role in the repair of a subset of DSBs via NHEJ [35], the expressions of ATM and phospho-ATM (p-ATM) were also analyzed. Notably, our data showed that olaparib treatment increased the expression of p-ATM, which indicated the activation of ATM upon DNA damage. In contrast, combining PSPC1 siRNA with olaparib promoted a considerable decrease in the expression of p-ATM (Figure 2A,B). Overall, PSPC1 inhibition enhanced DNA damage in the presence of olaparib by suppressing the expression of DDR proteins induced by olaparib. 2.3. Mitotic Catastrophe Caused by Combination Treatment Could Explain the Synergistic Mechanisms Our observation of an increase in DNA DSBs after combination treatment motivated us to investigate how cell cycle distribution was influenced by olaparib and PSPC1 siRNA treatment. However, our cell cycle analysis in BT−474 cells showed that combination treatment promoted a greater accumulation (36.84%) of G2/M phase cells than did olaparib (30.23%) and PSPC1 siRNA (23.36%) alone. In addition, the sub-G1 population, which is an indicator of apoptotic cell death, was slightly increased (2%) after combination treatment with olaparib and PSPC1 siRNA, compared to olaparib alone (1.74%) (Figure 3A). Cell cycle analysis in SNU−251 cells also showed results similar to those for BT−474 cells. The data showed that 17.63% of the cells were accumulated in the G2/M phase after olaparib treatment, which increased to 21.97% when olaparib was combined with PSPC1 siRNA. Similarly, combination therapy promoted greater accumulation of cells in the sub-G1 phase (21.30%) than did olaparib (10.03%) and PSPC1 siRNA (3.91%) alone, indicating that adding olaparib to PSPC1 siRNA enhanced apoptotic cell death (Figure 3B). To further evaluate the molecular mechanism by which PSPC1 inhibition-induced ATM suppression regulated the cell cycle, we investigated the cell cycle transition-regulatory proteins, cell division cycle 25C (cdc25C) and cdc2, also known as cyclin dependent kinase 1 (CDK1) [36], using Western blotting. ATM is known to play key roles in checkpoint activation via Chk1/checkpoint kinase 2 (Chk2) upon DNA DSBs [37]. Specifically, phospho-Chk1 (activated by p-ATM) has been reported to inactivate cdc25C by phosphorylation on serine-216, which prevents dephosphorylation of cdc2, resulting in the suppression of CDK1/cyclin B complex, thereby inducing G2/M checkpoint activation [38]. We observed that the expressions of phospho-cdc25C [p-cdc25C (Ser216)] and phospho-cdc2 [p-cdc2 (Tyr15)] were increased after olaparib treatment, suggesting that the G2/M checkpoint was activated. However, combining PSPC1 siRNA with olaparib decreased the expressions of those two proteins again, indicating that the G2/M transition occurred due to the p-ATM suppression (by PSPC1 siRNA)-induced activation of cdc25C (Figure 3C,D). Mitotic catastrophe caused by combination treatment could explain the synergistic mechanisms. (A,B) BT−474 and SNU−251 cells were treated with 5 nM of PSPC1 siRNA, olaparib (IC50 concentration in BT−474 and half IC50 concentration in SNU−251), and their combination for 72 h. Cell cycle distribution was assessed by flow cytometry after staining with PI. The histogram exhibited the distribution of cells in various phases (G0/G1, S, and G2/M) and the bar graphs represented the percentage of cells in G0/G1, S, and G2/M phases of cell cycle. (C,D) Western blot was carried out to check the expression of cell cycle progression-related proteins such as p-cdc25C and p-cdc2. (C) BT−474 and (D) SNU−251 cells were treated with 5 nM of PSPC1 siRNA, olaparib (IC50 concentration in BT-474 and half IC50 concentration in SNU−251), and their combination for 72 h. GAPDH was used as a loading control. (E) Graphical view of the proposed mechanism. Olaparib induced inhibitory phosphorylation of CDK1 causes mitotic exit which is reversed by PSPC1 inhibition (due to PSPC1 inhibition induced ATM and DNA-PKcs suppression), eventually premature mitotic entry occurred of the DNA-damaged cells, leading to mitotic catastrophe. Taken together, PSPC1 inhibition in combination with olaparib prevented G2/M checkpoint activation and then enhanced the G2/M transition. Hence, cells with damaged DNA enter mitosis, leading to mitotic catastrophe (Figure 3E). 2.4. Combination of PSPC1 siRNA and Olaparib Inhibits Tumor Growth in a PSPC1-Expressing BRCA2-Mutated Breast Cancer Xenograft Model We subsequently evaluated the in vivo efficacy of olaparib, PSPC1 siRNA, and their combination in a BT−474 xenograft mouse model. The schedule of the animal experiments is depicted in Figure 4A. First of all, PSPC1 siRNA or the combination used in this study were well tolerated, and no generalized toxicity was observed given that the body weight remained normal (Figure 4B). Combining PSPC1 siRNA with olaparib promoted greater tumor regression than did PSPC1 siRNA alone (p = 0.211), olaparib alone (p < 0.0001), and control siRNA (p < 0.0001) (Figure 4C). The individual tumor volumes were shown in Figure 4D. Remarkably, combination treatment exhibited complete tumor regression in two out of the six mice (Figure 4E). PSPC1 siRNA alone also significantly inhibited the tumor growth, including complete tumor regression in one mouse, compared to control siRNA (p < 0.0001). Finally, the mice were sacrificed on day 16, and the tumors were excised for further experiments. After subjecting tumor tissue lysates to Western blot analysis, we observed a similar pattern of expression in the genes tested in vitro. Briefly, combination therapy markedly reduced the expression of DDR-related genes, such as p-ATM and DNA-PKcs. In addition, combination therapy promoted greater inhibition of the expression of cell cycle-related genes, p-cdc25C (Ser216) and p-cdc2 (Tyr15), than did monotherapy, indicating that the G2/M transition occurred (Figure 4F). Lastly, the expression of cleaved caspase-3 was noticeably elevated, suggesting increased apoptosis (Figure 4G). Combination of PSPC1 siRNA and olaparib inhibits tumor growth in a PSPC1-expressing BRCA2-mutated breast cancer xenograft model. (A) Graphical view of drug treatment schedule and animal experimental procedure. (B) The body weights of mice exhibited that the treated doses were well tolerated as weight loss was not observed (C) Mean tumor growth inhibition curves in mice which were treated with olaparib, PSPC1 siRNA, and their combination. Tumor volumes were measured three times a week by a vernier caliper. Indicated p-values were calculated by one-way ANOVA analysis on day 16 of treatment, whereas ** p < 0.01, *** p < 0.001, **** p < 0.0001. (D) Individual tumor volumes were shown on day 16. Data are presented as the mean ± SEM. (E) Photo of the excised tumors of each group shown after sacrificing on day 16. The red dotted circles indicate complete regression of the tumor (F) Western blot using BT−474 xenografted tumors after 16 days of treatment. Combination treatment suppressed the expression of DDR-associated genes, such as p-ATM, DNA-PKcs, p-cdc25C, and p-cdc2 compared to monotherapy. (G) Western blot using BT−474 xenografted tumors after 16 days of treatment. The expression of the apoptosis marker cleaved caspase-3 was increased after combination treatment compared to monotherapy. 2.5. High PSPC1 Expression Is Associated with Poor Prognosis in Breast and Ovarian Cancer We investigated the impact of PSPC1 overexpression on prognosis using independent public mRNA expression data sets. The PSPC1-High group (≥median) exhibited a higher recurrence risk than that of the PSPC1-Low group (